Issue 1/2021
Content (23 Articles)
Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues
Ankur Jindal, Manoj Kumar
Is it time to spit? More evidence for the oral–gut–liver axis in liver disease
Chathur Acharya, Jasmohan S. Bajaj
Management of primary sclerosing cholangitis and its complications: an algorithmic approach
Michal Prokopič, Ulrich Beuers
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Yana Geng, Klaas Nico Faber, Vincent E. de Meijer, Hans Blokzijl, Han Moshage
Regression of portal hypertension: underlying mechanisms and therapeutic strategies
Sonia Selicean, Cong Wang, Sergi Guixé-Muntet, Horia Stefanescu, Norifumi Kawada, Jordi Gracia-Sancho
Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB
Wei Xu, Qiang Li, Chenlu Huang, Qiankun Hu, Xun Qi, Yuxian Huang, Jiming Zhang, Liang Chen
Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B
Gang Hu, Ming X. Huang, Wei Y. Li, Chong J. Gan, Wen X. Dong, Xiao M. Peng
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
Matt Liu, Tai-Chung Tseng, Dae Won Jun, Ming-Lun Yeh, Huy Trinh, Grace L. H. Wong, Chien-Hung Chen, Cheng-Yuan Peng, Sung Eun Kim, Hyunwoo Oh, Min-Sun Kwak, Michael Cheung, Hidenori Toyoda, Yao-Chun Hsu, Jae Yoon Jeong, Eileen L. Yoon, Teerapat Ungtrakul, Jian Zhang, Qing Xie, Sang Bong Ahn, Masaru Enomoto, Jae-Jun Shim, Chris Cunningham, Soung Won Jeong, Yong Kyun Cho, Eiichi Ogawa, Rui Huang, Dong-Hyun Lee, Hirokazu Takahashi, Pei-Chien Tsai, Chung-Feng Huang, Chia-Yen Dai, Cheng-Hao Tseng, Satoshi Yasuda, Ritsuzo Kozuka, Jiayi Li, Christopher Wong, Clifford C. Wong, Changqing Zhao, Joseph Hoang, Yuichiro Eguchi, Chao Wu, Yasuhito Tanaka, Ed Gane, Tawesak Tanwandee, Ramsey Cheung, Man-Fung Yuen, Hyo-Suk Lee, Ming-Lung Yu, Jia-Horng Kao, Hwai-I. Yang, Mindie H. Nguyen
Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy
Xiaoning Wu, Jialing Zhou, Yameng Sun, Huiguo Ding, Guofeng Chen, Wen Xie, Hongxin Piao, Xiaoyuan Xu, Wei Jiang, Hui Ma, Anlin Ma, Yongpeng Chen, Mingyi Xu, Jilin Cheng, Youqing Xu, Tongtong Meng, Bingqiong Wang, Shuyan Chen, Yiwen Shi, Yuanyuan Kong, Xiaojuan Ou, Hong You, Jidong Jia
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis
Jean-Frédéric Blanc, Faiza Khemissa, Jean-Pierre Bronowicki, Carole Monterymard, Jean-Marc Perarnau, Vincent Bourgeois, Stéphane Obled, Meher Ben Abdelghani, Isabelle Mabile-Archambeaud, Roger Faroux, Jean-François Seitz, Christophe Locher, Hélène Senellart, Anne-Laure Villing, Franck Audemar, Charlotte Costentin, Gaël Deplanque, Sylvain Manfredi, Julien Edeline, Evelyne Boucher, Marie Talarmin, Samuel Le Sourd, Julien Vergniol, Alice Gagnaire, Laurent Bedenne, Jean-Louis Jouve, Patrick Hillon, Côme Lepage, Anne Minello, Hélène Barraud, Thierry Lecomte , Jean-Pierre Barbieux, Patrice Wolff, Valérie Phoutthasang, Christine Belletier, Isabelle Archambeaud, Tamara Matysiak Budnik, Matthieu Schnee, Muriel Duluc, Emmanuelle Norguet Monnereau, Jaafar Bennouna, Sandrine Hiret, Michel Gatineau, Mohamed Ramdani, Yann Le Bricquir, Nathalie Ganne-Carrie, Valérie Bourcier, Christophe Pilette, Barbara Dauvois, Mathieu Baconnier, Pierre Michel, Philippe Thevenet, Hélène Cosme-Gassmann, François Habersetzer, Camélia Coltescu, Mathieu Pauwels, Sophie Nahon Brissonneau, Joëlle Egreteau, Jérôme Desrame, Dominique Auby, Patrick Texereau, Pierre-Luc Etienne, Louis-Marie Dourthe, Youssef Tazi
One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment
Tai-Chung Tseng, Jonggi Choi, Mindie H. Nguyen, Cheng-Yuan Peng, Spyros Siakavellas, George Papatheodoridis, Chia-Chi Wang, Young-Suk Lim, Hsueh-Chou Lai, Huy N. Trinh, Christopher Wong, Clifford Wong, Jian Zhang, Jiayi Li, Jia-Horng Kao
S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma
Lu-Nan Qi, Liang Ma, Fei-Xiang Wu, Yuan-Yuan Chen, Wan-Ting Xing, Zhi-Jun Jiang, Jian-Hong Zhong, Zu-Shun Chen, Wen-Feng Gong, Jia-Zhou Ye, Hong-Hao Li, Jin-Jie Shang, Bang-De Xiang, Le-Qun Li
Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study
Qiuyue Ma, Fude Yang, Botao Ma, Wenzhan Jing, Jue Liu, Moning Guo, Juan Li, Zhiren Wang, Min Liu
Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation
Soon Kyu Lee, Jeong Won Jang, Heechul Nam, Pil Soo Sung, Hee Yeon Kim, Jung Hyun Kwon, Sung Won Lee, Do Seon Song, Chang Wook Kim, Myeong Jun Song, Ho Joong Choi, Young Kyoung You, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Acute liver failure in Budd–Chiari syndrome and a model to predict mortality
Paul J. Thuluvath, Joseph J. Alukal, Talan Zhang
Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis
Xin Zeng, Xia Sheng, Pei-Qin Wang, Hai-Guang Xin, Yi-Bin Guo, Yong Lin, Jia-Wei Zhong, Cheng-Zhi He, Jie Yin, Tao-Tao Liu, Wei-Juan Ma, Xiao Xiao, Pei-Mei Shi, Zong-Li Yuan, Ling Yang, Xiong Ma, Jian-Ming Xu, Xi-Zhong Shen, Chang-Qing Yang, Xuan Zhu, Nong-Hua Lv, Wei-Fen Xie
GATA6 modulates the ductular reaction to bile duct ligation
Marjut Pihlajoki, Tea Soini, Rebecca B. Cochran, Emmi Liljeström, Jiansheng Huang, David A. Rudnick, Dennis J. Dietzen, Antti Kyrönlahti, Mikko P. Pakarinen, Markku Heikinheimo, David B. Wilson
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
Fu-Shun Yen, James Cheng-Chung Wei, Hei-Tung Yip, Chii-Min Hwu, Ming-Chih Hou, Chih-Cheng Hsu
Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis
Y. Lapidot, A. Amir, S. Ben-Simon, E. Veitsman, O. Cohen-Ezra, Y. Davidov, P. Weiss, T. Bradichevski, S. Segev, O. Koren, Z. Ben-Ari, M. Safran
Implications of liver injury in risk-stratification and management of patients with COVID-19
Jiaofang Shao, Yuan Liang, Yan Li, Rong Ding, Mengyan Zhu, Wenhua You, Ziyu Wang, Bin Huang, Min Wu, Tingting Zhang, Kening Li, Wei Wu, Lingxiang Wu, Qianghu Wang, Xinyi Xia, Shukui Wang, Ling Lu
Reductions in liver cirrhosis hospitalizations during the COVID-19 pandemic
Jianglei Li, Deliang Liu, Jin Yan, Yuyong Tan
How can we reduce the impact of COVID-19 pandemic on timely access to liver transplantation in children?
Mettu Srinivas Reddy, Jagadeesh Menon, Abdul Rahman Hakeem, Shivakumar Murugesan, Gomathy Narasimhan, Naresh Shanmugham, Mohamed Rela
Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates
Haiyan Yang, Jie Xu, Xuan Liang, Li Shi, Yadong Wang